二甲双胍治疗多囊肾病随机试验(TAME PKD)主要结果
这项2期两年试验将97例18-60岁、eGFR>50 ml/min/1.73 m2的ADPKD患者按1:1随机分配至二甲双胍或安慰剂组,每日两次。主要结局为药物安全性和耐受性,次要结局包括eGFR下降和总肾脏体积增长。二甲双胍安全且耐受性良好,eGFR年变化为-1.71 vs -3.07 ml/min/1.73 m2/年(平均差1.37 {-0.70, 3.44}),但差异未达显著;需更大样本试验评估疗效。
要点
- 二甲双胍在ADPKD成人中安全且耐受性良好。
- eGFR年下降二甲双胍组-1.71 vs 安慰剂组-3.07 ml/min/1.73 m2/年,差异不显著。
- 身高校正总肾脏体积年变化百分比3.87% vs 2.16%,差异不显著。
核心结论
- 二甲双胍在ADPKD成人中安全且耐受性良好,可轻微减少eGFR下降但未达显著程度。
- 评估疗效需更大样本、有足够把握度检测终点差异的试验。
研究设计与样本
- 2期、两年、随机、安慰剂对照试验。
- 97例18-60岁、eGFR>50 ml/min/1.73 m2的ADPKD患者,按1:1随机分配至二甲双胍或安慰剂,每日两次。
- 主要结局为药物安全性和耐受性;次要结局包括eGFR下降和总肾脏体积增长。
主要发现
- 两组发生严重不良事件的比例相似。
- 胃肠道症状评定量表评分基线低且随时间无显著变化。
- eGFR年变化:二甲双胍组-1.71,安慰剂组-3.07 ml/min/1.73 m2/年(平均差1.37 {-0.70, 3.44} ml/min/1.73 m2)。
关键数值与推荐
- 主要结局为药物安全性和耐受性。
- 次要结局包括eGFR下降和总肾脏体积增长。
临床怎么用
- 二甲双胍在ADPKD成人中可考虑使用,因其安全且耐受性良好。
- 目前证据尚不支持二甲双胍作为延缓ADPKD进展的常规治疗,需更大试验验证疗效。
局限性
- 样本量97例,可能不足以检测eGFR下降和总肾脏体积增长的显著差异。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by growth of kidney cysts and glomerular filtration rate (GFR) decline. Metformin was found to impact cystogenesis in preclinical models of polycystic disease, is generally considered safe and may be a promising candidate for clinical investigation in ADPKD. In this phase 2 two-year trial, we randomly assigned 97 patients, 18-60 years of age, with ADPKD and estimated GFR over 50 ml/min/1.73 m2, in a 1:1 ratio to receive metformin or placebo twice daily. Primary outcomes were medication safety and tolerability. Secondary outcomes included estimated GFR decline, and total kidney volume growth. Thirty-eight metformin and 39 placebo participants still received study product at 24-months. Twenty-one participants in the metformin arm reduced drug dose due to inability to tolerate, compared with 14 in the placebo arm (not significant). Proportions of participants experiencing serious adverse events was similar between the groups. The Gastrointestinal Symptoms Rating Scale score was low at baseline and did not significantly change over time. The annual change for estimated GFR was -1.71 with metformin and -3.07 ml/min/1.73m2 per year with placebo (mean difference 1.37 {-0.70, 3.44} ml/min/1.73m2), while mean annual percent change in height-adjusted total kidney volume was 3.87% in metformin and 2.16% per year in placebo, (mean difference 1.68% {-2.11, 5.62}). Thus, metformin in adults with ADPKD was found to be safe and tolerable while slightly reducing estimated GFR decline but not to a significant degree. Hence, evaluation of efficacy requires a larger trial, with sufficient power to detect differences in endpoints.
引用
- Perrone RD, Abebe KZ, Watnick TJ, et al. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int. 2021. PMID: 34186056. doi:10.1016/j.kint.2021.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。